325 Capital’s Lifecore Biomedical LFCR Stock Holding History

325 Capital’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.2M	Buy	2,895,881 +733,415	+34%	+$3.69M	3.62%	9
2026 Q1	$8.04M	Hold	2,162,466	–	–	2.93%	9
2025 Q4	$17.7M	Hold	2,162,466	–	–	6.2%	7
2025 Q3	$15.9M	Hold	2,162,466	–	–	4.84%	8
2025 Q2	$17.6M	Hold	2,162,466	–	–	6.93%	8
2025 Q1	$15.2M	Hold	2,162,466	–	–	6.31%	7
2024 Q4	$16.1M	Buy	2,162,466 +792,681	+58%	+$5.06M	6.21%	8
2024 Q3	$6.75M	Buy	1,369,785 +29,187	+2%	+$152K	2.86%	9
2024 Q2	$6.88M	Hold	1,340,598	–	–	2.89%	12
2024 Q1	$7.12M	Buy	1,340,598 +133,629	+11%	+$956K	3.29%	10
2023 Q4	$7.47M	Buy	+1,206,969	New	+$8.38M	3.7%	10

Other funds holding LFCR

Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

QOP

Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return

DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return

325 Capital's LFCR Position: Q2 2026 in Review

325 Capital increased its Lifecore Biomedical (LFCR) stake by 34% in Q2 2026, buying an estimated $3.69M and bringing the position to 2,895,881 shares worth $15.2M. The position accounts for 3.62% of the portfolio, ranked #9.

325 Capital first reported a position in LFCR in Q4 2023 and has held it in 11 quarters since. The position peaked at $17.7M in Q4 2025. 99 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

325 Capital held 2,895,881 shares of Lifecore Biomedical worth $15.2M as of Q2 2026.
325 Capital bought 733,415 Lifecore Biomedical shares in Q2 2026, an estimated $3.69M.
Lifecore Biomedical made up 3.62% of 325 Capital's portfolio in Q2 2026, its #9 holding.
325 Capital first reported a position in Lifecore Biomedical in Q4 2023 and has held it in 11 quarters since.
325 Capital's Lifecore Biomedical position peaked at $17.7M in Q4 2025.
99 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on 325 Capital's 13F filing for Q2 2026, filed 14 Aug 2026.